Britanin alleviates myocardial damage in rats with acute myocardial infarction by inhibiting the JAK2/STAT3 signaling pathway.

Figures

• 

  Figure 1. A) Molecular structure of Britanin. B) Protein-protein interaction (PPI) network diagram. C) Venn diagram of predicted targets of Britanin and targets of acute myocardial infarction (AMI). D) Top 10 targets obtained by the degree algorithm using Cytoscape software

• 

  Figure 2. Enrichment analysis results and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway association visualization

• 

  Figure 3. A) Macroscopic and microscopic three-dimensional molecular docking models of Britanin and JAK2 (8BA3). B) Macroscopic and microscopic three-dimensional molecular docking models of Britanin and PTGS2 (5F19). C) Macroscopic and microscopic three-dimensional molecular docking models of Britanin and CREBBP (4NYX). D) Macroscopic and microscopic three-dimensional molecular docking models of Britanin and EGFR (5CNO). E) Macroscopic and microscopic three-dimensional molecular docking display of Britanin and ABCB1 (8Y6I) without hydrogen bond formation

• 

  Figure 4. A). Britanin toxicity radar chart is designed to quickly illustrate the confidence of positive toxicity results compared to the class average. B) ProTox3.0-predicted median lethal dose (LD₅₀) curve of Britanin and its toxicity classification. The LD₅₀ curve illustrates the relationship between Britanin dosage and the corresponding mortality rate in the prediction model. The predicted median lethal dose (LD₅₀) of Britanin was determined to be 150 mg/kg, which lies within the range of 50–300 mg/kg and is therefore classified as moderately toxic. The vertical dashed lines mark the experimental doses (5 mg/kg and 10 mg/kg) used in this study, which are significantly lower than the LD₅₀ value, indicating good safety of Britanin at the applied doses

• 

  Figure 5. A) Echocardiographic images of rats in each group before surgery. B) Echocardiographic images of rats in each group on the 8th day after surgery. C-H) Statistical analysis of echocardiographic parameters of ejection fraction (EF), left ventricular fractional shortening (LVFS), left ventricular internal dimension at end-systole (LVIDS), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), left ventricular internal dimension at end-diastole (LVIDD) in each group before surgery. I-O) Statistical analysis of echocardiographic parameters of EF, LVFS, LVIDS, LVESV, LVEDV, LVIDD in each group on the 14th day after surgery

• 

  Figure 6. A) Representative cardiac images of rats in each group. B) Triphenyltetrazolium Chloride (TTC) staining of myocardial infarction among groups. C) Statistical analysis of TTC staining; D) Masson staining results of cardiac tissues of rats in each group. E) Proportion of fibrotic area in Masson staining of cardiac tissues of rats in each group. F) Statistical analysis of Masson staining. G) Sirius Red staining of cardiac tissues of rats in each group

• 

  Figure 7. Effects of Britanin on serum myocardial enzyme levels, liver and kidney function indices, and blood lipid profiles in rat experimental groups

• 

  Figure 8. Effects of Britanin on rat protein expression levels of Janus kinase 2/ signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway-related proteins and NOD-Like receptor pyrin domain-containing 3 (NLRP3) inflammasome-associated cytokines detected by Western blotting

• 

  Figure 9. Effects of Britanin on the protein expression levels of myocardial pyroptosis-related molecules in acute myocardial infarction (AMI) rats